Table 1.
Clinical characterisctics of patients
| Andexanet | Usual care | ||
|---|---|---|---|
| Number of patients | 23 | 26 | |
| Mean age | 78.4 | 76.6 | |
| Gender (M/F) | 8/15 | 14/12 | |
| Past history | |||
| Hypertention | 23 | 18 | |
| Atrial fibrillation | 18 | 3 | |
| Cerebrovascular disorders | 10 | 8 | |
| Location of spontaneous hemorrhage | |||
| Basal ganglia | 8 | 12 | |
| Cerebellum | 3 | 1 | |
| Pons | 2 | 0 | |
| Subcortex | 1 | 1 | |
| Diangnosis of traumatic hemorrhage | |||
| Contusional hematoma | 5 | 2 | |
| Acute subdural hematoma | 4 | 7 | |
| traumatic SAH | 0 | 3 | |
| Type of DOAC | |||
| Apixaban | 5 | 9 | |
| Rivaroxaban | 8 | 4 | |
| Edoxaban | 10 | 13 | |
| Mean time from last dose to CT (hours) | 9.7 | 9.6 | |
| 1 to 10 hours | 14 | 15 | |
| 11 to 18 hours | 9 | 11 | |
| Hematoma volume (mL) | 45.5 | 15.4 | |
| < 30 mL | 10 | 21 | |
| 30–80 mL | 8 | 30 | |
| > 80 mL | 5 | 1 | |
| Hematoma expansion or event of difficult hemostasis | 1 | 4 | |
| Thromboenbolic events | 2 | - | |
| Outcome (mRS) | 0 to 3 | 9 | 13 |
| 4 and 5 | 11 | 10 | |
| 6 | 3 | 3 |
Fig. 1.
Clinical course of the study cases
Fig 2.
88 year-old male with rivaroxaban intake. Traumatic intracerebral and intraventricular hemorrhages. Andexanet alfa was administered after hematoma expansion was observed at day 1. a: at ambulance, b: Day1 Right frontal intracerebral hematoma was enlarged., c: Day2, No hematoma expansion 24h after andexanet administration
Fig. 3.
82 year-old female with edoxaban intake. Right acute subdural hematoma. Andexanet administration. a: at ambulance, b: 14h after andexanet administration, c: 14 days after the ambulance.